MiR-483-5p controls angiogenesis in vitro and targets serum response factor

66Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Angiogenesis, a key factor in ischemic heart disease, is rapidly initiated in response to hypoxic or ischemic conditions. MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that regulate gene expression at post-transcriptional level. The recent discovery of the involvement of these RNAs in the control of angiogenesis renders them very attractive in the development of new approaches for restoring the angiogenic balance. In the present study, we explored that miR-483-5p, a microRNA embedded in the intron of insulin-like growth factor 2 (Igf2), acts as an endogenous angiogenesis- inhibiting factor. We identified that serum response factor (SRF) is one of miR-483-5p target genes. These findings indicated that the miR-483-5p-SRF pathway may offer a novel strategy for treatment with angiogenesis in ischemic heart disease patients. © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Qiao, Y., Ma, N., Wang, X., Hui, Y., Li, F., Xiang, Y., … Gao, X. (2011). MiR-483-5p controls angiogenesis in vitro and targets serum response factor. FEBS Letters, 585(19), 3095–3100. https://doi.org/10.1016/j.febslet.2011.08.039

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free